Next Article in Journal / Special Issue
The Implications of Cancer Stem Cells for Cancer Therapy
Previous Article in Journal
Recent Advances in Nanoparticle-Based Förster Resonance Energy Transfer for Biosensing, Molecular Imaging and Drug Release Profiling
Previous Article in Special Issue
Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice
Int. J. Mol. Sci. 2012, 13(12), 16624-16635; doi:10.3390/ijms131216624

Modulation of MDR1 and MRP3 Gene Expression in Lung Cancer Cells after Paclitaxel and Carboplatin Exposure

1,†,* , 2
1 Institute of Biopathology and Regenerative Medicine (IBIMER), Department of Anatomy and Human Embryology, School of Medicine, University of Granada, Granada E-18071, Spain 2 Service of Medical Oncology, Virgen de las Nieves Hospital, Granada E-18012, Spain 3 Department of Health Science, University of Jaén, Jaén E-23071, Spain These authors contributed equally to this work.
* Author to whom correspondence should be addressed.
Received: 28 September 2012 / Revised: 20 November 2012 / Accepted: 26 November 2012 / Published: 5 December 2012
(This article belongs to the Special Issue Advances in Molecular Oncology (special issue))
View Full-Text   |   Download PDF [458 KB, uploaded 19 June 2014]   |   Browse Figures


Carboplatin-paclitaxel is a reference regimen in the treatment of locally advanced or disseminated non-small cell lung cancer (NSCLC). This paper discusses the multidrug resistance developed with this drug combination, which is one of the major obstacles to successful treatment. In order to understand and overcome the drug resistance pattern of NSCLC after carboplatin plus paclitaxel exposure, levels of mRNA expression of multidrug resistance 1 (MDR1) and multidrug resistance-associated protein 3 (MRP3) were investigated in primary NSCLC cell lines (A-549 and A-427) and a metastasis-derived NSCLC cell line (NODO). Our results showed that exposure of the three NSCLC lines to plasma concentrations of paclitaxel (5 μM) produced an increase in MDR1 expression, while MRP3 showed no alteration in expression. By contrast, the same cells exposed to carboplatin plasma concentrations (30 μM) showed overexpression of MRP3. In these cells, MDR1 showed no expression changes. Interestingly, the combination of both paclitaxel and carboplatin caused increased expression of the MDR1 drug resistance gene rather than the individual treatments. These results suggest that carboplatin and paclitaxel may induce drug resistance mediated by MDR1 and MRP3, which may be enhanced by the simultaneous use of both drugs.
Keywords: lung cancer; resistance; MDR; MRP; paclitaxel; carboplatin lung cancer; resistance; MDR; MRP; paclitaxel; carboplatin
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
MDPI and ACS Style

Melguizo, C.; Prados, J.; Luque, R.; Ortiz, R.; Caba, O.; Álvarez, P.J.; Gonzalez, B.; Aranega, A. Modulation of MDR1 and MRP3 Gene Expression in Lung Cancer Cells after Paclitaxel and Carboplatin Exposure. Int. J. Mol. Sci. 2012, 13, 16624-16635.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


Cited By

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert